Back to Health

Can You Get HIV Treatment as a Long-Acting Injection?

Can You Get HIV Treatment as a Long-Acting Injection?
Bareback Guide 4 February 2026

Long-acting injectable HIV treatment exists and is available on the NHS through specialist clinics to people who meet the criteria. Instead of a daily tablet, two injections are given at the clinic every two months. For people who find daily dosing difficult, or for whom having tablets in the house is the problem, it changes the shape of treatment considerably.

What does it involve?

Two intramuscular injections into the buttock, given at the same appointment. The combination used is cabotegravir with rilpivirine. Most people start with a period on oral tablets to establish tolerance, though some services now initiate directly. After that, appointments are every two months, with a window either side to allow for holidays and scheduling.

Who is eligible?

Criteria vary between services but generally require a sustained undetectable viral load on current treatment, no known resistance to the two drug classes involved, no active hepatitis B requiring treatment, and a realistic ability to attend every two months. Because missing an injection creates a period of falling drug levels, reliability of attendance matters more than it does with tablets, which is a genuine consideration rather than a formality.

Why choose it?

The most common reasons are not medical. People choose it because daily tablets are a daily reminder of the diagnosis, because a housemate, family member or partner might find the medication, because their routine is too irregular for consistent dosing, or because they simply prefer six appointments a year to three hundred and sixty-five doses. Adherence to injections is generally excellent in people who choose them.

What are the drawbacks?

Injection site reactions are common: soreness, swelling or a lump lasting a few days after each appointment, which most people find tolerable but some do not. You have to attend the clinic every two months regardless of how well you are, which is more contact with services than some people want. And if you stop, drug levels decline slowly over months, which creates a long period of low levels where resistance could develop, so stopping has to be planned with oral cover rather than simply not returning.

What happens if you miss an appointment?

Contact the clinic immediately rather than waiting for the next one. There is a window of a few days either side of the due date, and beyond that the clinic will usually bridge with oral tablets until you can be reinjected. This is the single most important practical point about injectable treatment, and it is worth having the clinic's number saved before you need it.

Is it as effective?

Trials found it non-inferior to daily oral treatment for maintaining suppression in people who were already undetectable, which is why eligibility requires suppression first. It is a maintenance option rather than a starting regimen for most people.

What about injectable prevention?

Long-acting injectable PrEP is a separate development and availability in the UK has lagged behind treatment. Newer agents given every six months have been approved in some countries and are moving through regulatory and commissioning processes elsewhere. If a partner is asking, the honest answer is that provision is changing and their clinic will know the current local position.

How do you ask about it?

Raise it at your next clinic appointment. Not every service offers it, and some run it through a specific pathway with limited capacity, so the answer may be a waiting list rather than a yes or no. Say what the reason is, since the criteria are partly about whether it would solve a real problem for you.

Does it change your monitoring?

Not substantially. Viral load and the usual bloods continue on a similar schedule, and the injection appointments provide a natural point to take them. Some people find the regular contact reassuring and others find it intrusive, which is worth weighing honestly before switching.

What about hepatitis B?

This matters. Some oral regimens also suppress hepatitis B, and the injectable combination does not. Anyone with chronic hepatitis B who switches needs separate treatment for it, since stopping suppression can cause a serious flare. Your clinic will check this before offering the switch, but it is worth understanding why the question is asked.

Can you switch back?

Yes, and people do, most often because injection site reactions become tiresome or because the two-monthly appointments do not fit their life. Switching back to tablets is straightforward and is planned so there is no gap in cover.